Corporate Magazine 2012 - Boehringer Ingelheim

More documents

Recommendations

Info

“For me, the photo shows thatthe indirect view producesmore interesting perspectiveson things and people than asober examination of the facts.It brings details to light thatwe would otherwise never havediscovered.”wilhelm von heykinghead of development coordinationbiberach, germany48° 5' 53" N, 9° 47' 19" Ebiberach, germany
our businessesperspectives for better health#3.3BIOPHARMACEUTICALSBIOPHARMACEUTICALS –MEDICINES FOR THE FUTUREBoehringer Ingelheim was a pioneer in the field of biotechnologyand is now one of the leading companies for the development andmanufacture of biopharmaceuticals. New biological entities (NBEs)and biosimilars are and will continue to be among the main driversof growth in the pharmaceutical industry in the mid to long term.12 3New biologic entitiesOur Biopharmaceuticals business iscommitted to supporting research anddevelopment (R&D) of new biologicalentities.Biopharmaceuticals is an integral partof in-licensing activities and identificationof potential new products. It continuouslyscouts for innovative processand product technologies. These activitiesfoster the development of cuttingedgeNBEs in the respective therapeuticareas.Boehringer Ingelheim markets thefour biopharmaceuticals actilyse®,metalyse®, imukin® and beromun®produced in cell culture or from microbialfermentation.Boehringer Ingelheim BioXcellenceWe aspire to maintain our position asone of the world’s largest contract manufacturersof biopharmaceuticals, providingthe entire production technologychain from DNA to fill and finish. Wehave brought 22 new biopharmaceuticalproducts (or NBEs) together with ourcustomers to the market (i. e. cell-linedevelopment to registered product).The contract manufacturing business ofBoehringer Ingelheim is now representedby its new brand Boehringer IngelheimBioXcellence, which stands forexcellence, quality and reliability in themarket.Our biosimilarsIn addition, we decided to expand ourcurrent Biopharmaceuticals businessfor the development and manufactureof new and innovative biopharmaceuticalsinto developing biosimilars.With our expertise and world-classtechnology, we are well-placed tocreate, develop and manufacture highqualitybiosimilars.OUR BIOPHARMACEUTICALSNETWORK1 fremont, usa2 biberach, germany3 vienna, austriaBiopharmaceuticals – medicines for the future 93
Page 1 and 2:
Value through InnovationCorporate M
Page 3 and 4:
our businesses66 [ prescription med
Page 7:
value through innovationperspective
Page 10 and 11:
56° 40' 59" N, 5° 6' 14" Wglencoe
Page 12 and 13:
56° 40' 59" N, 5° 6' 14" Wglencoe
Page 14 and 15:
PERSPECTIVES FORSOCIETYIn all our a
Page 16 and 17:
50 NATIONSPeople from around 50 nat
Page 18 and 19:
“RLDP journey: a great learning o
Page 20 and 21:
SHONA MCDONALD, SHONAQUIP[ south af
Page 22 and 23:
SEHNAZ LAYIKEL, RUSIHAK[ turkey ]he
Page 24 and 25:
Thalita Guimaraes joins the “Boeh
Page 26 and 27:
When handling chemicals, employees
Page 28 and 29:
11 With its own wastewater treatmen
Page 30 and 31:
21 Dr Carolyn R. Bertozzi received
Page 32 and 33:
PERSPECTIVES FOR THE SOCIETYOF TOMO
Page 34 and 35:
The opening ceremony of IMB:Interac
Page 36 and 37:
CIRCUIT MECHANICS OF EMOTIONSUnders
Page 38 and 39:
BIBERACH UNIVERSITY OF APPLIEDSCIEN
Page 40 and 41:
22° 41' 0" S, 14° 32' 0" Eswakopm
Page 42 and 43:
22° 41' 0" S, 14° 32' 0" Eswakopm
Page 44 and 45:
PERSPECTIVES FORMEDICAL INNOVATIONB
Page 46 and 47:
RESEARCH PARTNERSHIPS WITHACADEMIA
Page 48 and 49: collaborate innovate accelerateTRAN
Page 50 and 51: GLORIA-AF®Registry programme for p
Page 52 and 53: BOEHRINGER INGELHEIM ONCOLOGY FRANC
Page 54 and 55: AFATINIB BLOCKS THE ERBB RECEPTORSE
Page 56 and 57: HEPTATIS C VIRUS (HCV) INFECTIONHCV
Page 58 and 59: 1viral entryrnareleasernatranslated
Page 60 and 61: 12THE MAIN COMPLICATIONS OF DIABETE
Page 62 and 63: ASTHMAAsthma is a chronic disease c
Page 64 and 65: THERAPEUTIC AREA (TA) REVIEW CORE T
Page 66 and 67: 6° 59' 15" N, 125° 16' 15" Eapo,
Page 68 and 69: icardo f. solitariadistrict manager
Page 70 and 71: PERSPECTIVES FORBETTER HEALTHBoehri
Page 72 and 73: “My photo shows Frau Röhrigfrom
Page 74 and 75: OUR CARDIOVASCULAR PORTFOLIOaggreno
Page 76 and 77: HOW ATRIAL FIBRILLATION (AF)LEADS T
Page 78 and 79: FINDING THE RIGHT MOLECULE“Findin
Page 80 and 81: PATIENTS AT CARDIOVASCULAR RISKMost
Page 82 and 83: TRAJENTA® / TRADJENTA®trajenta®
Page 84 and 85: WORLD DIABETES DAYWorld Diabetes Da
Page 86 and 87: SPIRIVA®: 10 YEARS AND MORE OF CLI
Page 88 and 89: BEHAVIOUR CHANGE INTYPE 2 DIABETEST
Page 90 and 91: Rapid progress in global healthcare
Page 92 and 93: KEY GOALS OF GLOBAL BUSINESS SERVIC
Page 94 and 95: “The perspectives that open upune
Page 96 and 97: OUR GLOBAL SWITCH TEAMThe Switch un
Page 100 and 101: 2 Disposable single use bioreactorw
Page 102 and 103: “The hard-working beessuccessfull
Page 104 and 105: “There are many things and experi
Page 106 and 107: OUR GLOBAL SCIENTIFIC NET WORKIN AN
Page 108 and 109: 2 31 Scientists in Hannover working
Page 110 and 111: “Living and working on a differen
Page 112 and 113: 1 Phoenix, the first captive-bredOr
Page 114 and 115: 55° 21' 0" N, 131° 40' 24" Wketch
Page 116 and 117: scott zhangstrategic effectiveness
Page 118 and 119: PERSPECTIVES FORQUALITY IN OPERATIO
Page 120 and 121: With the quality risk management sy
Page 122 and 123: In order to ensure patient safety,
Page 124 and 125: 37° 34' 48" N, 14° 16' 34" Esicil
Page 126 and 127: 37° 34' 48" N, 14° 16' 34" Esicil
Page 128 and 129: PERSPECTIVES FORESTABLISHED MARKETS
Page 130 and 131: Spain is one of the countries struc
Page 132 and 133: 21 View of Athens.2 Production site
Page 134 and 135: 1 View of San Francisco, the leadin
Page 136 and 137: 211 View of Tokyo with Japan’s hi
Page 138 and 139: IF YOU HAVE ANY QUERIES OR COMMENTS
Page 140 and 141: Value through InnovationBusiness Ye
Page 142 and 143: product portfolio70 [ branded presc
Page 144 and 145: usiness year 2012our companyOUR COM
Page 146 and 147: usiness year 2012the shareholders
Page 148 and 149:
usiness year 2012the shareholders
Page 150 and 151:
usiness year 2012 key aspects 2012S
Page 152 and 153:
usiness year 2012 key aspects 2012F
Page 154 and 155:
usiness year 2012 key aspects 2012B
Page 156 and 157:
usiness year 2012corporate bodiesCO
Page 158 and 159:
usiness year 2012group management r
Page 160 and 161:
Page 162 and 163:
Page 164 and 165:
Page 166 and 167:
Page 168 and 169:
Page 170 and 171:
Page 172 and 173:
Page 174 and 175:
Page 176 and 177:
Page 178 and 179:
usiness year 2012consolidated finan
Page 180 and 181:
Page 182 and 183:
Page 184 and 185:
Page 186 and 187:
Page 188 and 189:
Page 190 and 191:
Page 192 and 193:
Page 194 and 195:
Page 196 and 197:
Page 198 and 199:
Page 200 and 201:
Page 202 and 203:
Page 204 and 205:
Page 206 and 207:
usiness year 2012auditor’s report
Page 208 and 209:
product portfolioa selection2012PRO
Page 210 and 211:
product portfoliobranded prescripti
Page 212 and 213:
Page 214 and 215:
Page 216 and 217:
Page 218 and 219:
Page 220 and 221:
product portfolioconsumer health ca
Page 222 and 223:
Page 224 and 225:
Page 226 and 227:
Page 228 and 229:
product portfolioanimal healthIndic
Page 230 and 231:
Page 232 and 233:
Page 234 and 235:
Page 236 and 237:
usiness year 2012financial data2006
Page 238:
www.boehringer-ingelheim.comannualr
show all

Corporate Magazine 2012 - Boehringer Ingelheim

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?